NICE guidance recommends new treatment option for people with common heart condition: In final guidance published today (15 March) NICE has recommended dabigatran (Pradaxa, Boehringer Ingelheim), in accordance with its licensed indications, as an option for the prevention of stroke and systemic embolism in people with atrial fibrillation.
NICE
No comments:
Post a Comment